Haemolytic disease of newborn

review article and a retrospective analysis of patients hospitalised at a tertiary neonatal centre during 2007-2016

  • Jana Lozar Krivec Division of Paediatrics, Department of Neonatology, University Medical Centre Ljubljana
  • Metka Vidaković Division of Paediatrics, Department of Neonatology, University Medical Centre Ljubljana
  • Aneta Soltirovska-Šalamon Division of Paediatrics, Department of Neonatology, University Medical Centre Ljubljana
Keywords: haemolysis, neonate, blood group, icterus, exchange transfusion


Haemolytic disease of the foetus and newborn (HDFN) occurs when maternal alloimmune antibodies cross the placenta to the foetal circulation and cause destruction of erythrocytes, resulting in anaemia and hyperbilirubinemia. It can result from naturally present antibodies, such as anti-A and anti-B antibodies, or isoantibodies produced by women previously sensitised during pregnancy or transfusion of incompatible erythrocytes such as anti-D antibodies. RhD antigen is the most immunogenic and causes severe HDFN, while the spectrum of HDFN due to AB0 incompatibility ranges from subclinical to severe, requiring exchange transfusion. Thanks to effective and widely implemented prophylaxis with administration of anti-D immunoglobulin to RhD negative women, the HDFN due to anti-D is nowadays a rare disease.
Present paper provides an overview on the pathophysiology, clinical characteristics, diagnostics, treatment and prevention of HDFN. In the second part of the article we present the results of a cohort retrospective analysis of 109 patients with HDFN hospitalised at the tertiary neonatal unit during 2007–2016. In 84.4 % of cases the underlying cause of HDFN were antibodies anti-A or anti-B, in 9.2 % of cases antibodies anti-D and in 6.4 % other more rare antibodies. HDFN caused by different antibodies did not result in statistically significant differences in the evaluated hematological tests. Direct Coombs test was positive in all patients with HDFN RhD and in 64 % of newborns with HDFN AB0. All patients with HDFN RhD required exchange transfusion or intrauterine transfusion.


Download data is not yet available.


Rennie JM. Rennie&Roberton’s TextbookofNeonatology, 5thedition. Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterminfants. Arch Dis Child Fetal Neonatal Ed. 2009;94(5):F317–22. PMID:19307221

Vir: NIJZ, Perinatalni informacijski sistem Republike. de Alarcon P, Werner E. Neonatal Hematology. Cambridge: Cambridge University Press; 2005.

Luchtman-Jones L, Schwartz AL, Wilson DB. The blood and hematopoietic system. Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine-Diseases of the Fetus and Infant. 8th ed. St. Louis, Mo: Mosby; 2006. Vol 2: 1287–1356.

Choavaratana R, Uer-Areewong S, Makanantakosol S. Feto-maternal transfusion in normal pregnancy and during delivery. J Med Assoc Thai. 1997 Feb;80(2):96–100. PMID:9078693

Bricl I, Ogrizek-Pelkič K, Vogler A. Hemolitična bolezen ploda in novorojenčka (HBPN) – prikaz primera. Zdrav Vestn. 2003;72:671–3.

Železnik K, Dovč-Drnovšek T, Rožman P, Bricl I. Preventiva in diagnostika hemolitične bolezni ploda in novorojenčka. Zdrav Vestn. 2012;81 supl 2:II-312–21.

Geaghan SM. Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. Semin Perinatol. 2011 Jun;35(3):148–54. https://doi.org/10.1053/j.semperi.2011.02.009 PMID:21641488

Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematology. 2006;22(4):188–95. PMID:17430078

Groleger K, Bratanič B, Veličkovič Perat M. Nekonjugirana hiperbilirubinemija pri novorojenčku. Med Razgl. 1998;37:355–66.

Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology (Am Soc Hematol Educ Program). 2015;2015(1):146–51. https://doi.org/10.1182/asheducation-2015.1.146 PMID:26637714

Christensen RD, Yaish HM. Hemolytic Disorders Causing Severe Neonatal Hyperbilirubinemia. Clin Perinatol. 2015 Sep;42(3):515–27. https://doi.org/10.1016/j.clp.2015.04.007 PMID:26250914

Christensen RD, Lambert DK, Henry E, Yaish HM, Prchal JT. End-tidal carbon monoxide as an indicator of the hemolytic rate. Blood Cells Mol Dis. 2015 Mar;54(3):292–6. https://doi.org/10.1016/j.bcmd.2014.11.018 PMID:25624169

Lozar-Krivec J, Bratanic B, Paro-Panjan D. The role of carboxyhemoglobin measured with CO-oximetry in the detection of hemolysis in newborns with ABO alloimmunization. J Matern Fetal Neonatal Med. 2016;29(3):452–6. https://doi.org/10.3109/14767058.2015.1004050 PMID:25604086

Christensen RD, Yaish HM, Henry E, Bennett ST. Red blood cell distribution width: reference intervals for neonates. J Matern Fetal Neonatal Med. 2015 May;28(8):883–8. https://doi.org/10.3109/14767058.2014.938044 PMID:24968099

Christensen RD, Henry E, Andres RL, et al. Neonatal reference ranges for blood concentrations of nucleated red blood cells. Neonatology. 2010;99:289–94. https://doi.org/10.1159/000320148 PMID:21135564

Herschel M, Karrison T, Wen M, Caldarelli L, Baron B. Evaluation of the direct antiglobulin (Coombs’) test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs’ test with ETCOc for detecting significant jaundice. J Perinatol. 2002 Jul-Aug;22(5):341–7. https://doi.org/10.1038/sj.jp.7210702 PMID:12082466

American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul;114(1):297–316. https://doi.org/10.1542/peds.114.1.297 PMID:15231951

Bhutani VK, Johnson-Hamerman L. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015 Feb;20(1):6–13. https://doi.org/10.1016/j.siny.2014.12.008 PMID:25577653

Wong RJ, Stevenson DK. Neonatal hemolysis and risk of bilirubin-induced neurologic dysfunction.

Kaplan M, Bromiker R, Hammerman C. Hyperbilirubinemia, hemolysis, and increased bilirubin neurotoxicity. Semin Perinatol. 2014 Nov;38(7):429–37. https://doi.org/10.1053/j.semperi.2014.08.006 PMID:25284470

Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008 Feb;358(9):920–8. https://doi.org/10.1056/NEJMct0708376 PMID:18305267

Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome. Expert Rev Hematol. 2017 Apr;10(4):337–44. https://doi.org/10.1080/17474086.2017.1305265 PMID:28277805

Sainio S, Nupponen I, Kuosmanen M, Aitokallio-Tallberg A, Ekholm E, Halmesmäki E, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015 Apr;94(4):383–90. https://doi.org/10.1111/aogs.12590 PMID:25603954

Lozar Krivec J. Izmenjalna transfuzija pri novorojenčkih. In: Obravnava kritično bolnih- od novorojenčka do odraslega. Zbornik prispevkov: 48. Strokovni seminar; Rogaška Slatina, maj 2015, Slovenija. V Ljubljani: Zbornica zdravstvene in babiške nege Slovenije - Zveza društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester in zdravstvenih tehnikov v anesteziologiji, intenzivni terapiji in transfuziologiji, 2015.

Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014 Jul;99(4):F325–31. https://doi.org/10.1136/archdischild-2013-304878 PMID:24514437

Daniels G, Finning K, Martin P. Noninvasive fetal blood grouping: present and future. Clin Lab Med. 2010 Jun;30(2):431–42. https://doi.org/10.1016/j.cll.2010.02.006 PMID:20513561

Christensen RD, Nussenzveig RH, Yaish HM, Henry E, Eggert LD, Agarwal AM. Causes of hemolysis in neonates with extreme hyperbilirubinemia. J Perinatol. 2014 Aug;34(8):616–9. https://doi.org/10.1038/jp.2014.68 PMID:24762414

Kristinsdottir T, Kjartansson S, Hardardottir H, Jonsson T, Halldorsdottir AM. [Positive Coomb’s test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012]. Laeknabladid. 2016 Jul;102(7-8):326–31. PMID:27531851

Valsami S, Politou M, Boutsikou Τ, Briana D, Papatesta M, Malamitsi-Puchner A. Importance of Direct Antiglobulin Test (DAT) in Cord Blood: Causes of DAT (+) in a Cohort Study. Pediatr Neonatol. 2015 Aug;56(4):256–60. https://doi.org/10.1016/j.pedneo.2014.11.005 PMID:25637293

Sarici SU, Yurdakök M, Serdar MA, Oran O, Erdem G, Tekinalp G, et al. An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility. Pediatrics. 2002 Apr;109(4):e53. https://doi.org/10.1542/peds.109.4.e53 PMID:11927726

How to Cite
Lozar Krivec J, Vidaković M, Soltirovska-Šalamon A. Haemolytic disease of newborn. ZdravVestn [Internet]. 28Oct.2018 [cited 17Jan.2019];87(9-10):405-16. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/2659